Ivonescimab Shows Positive Overall Survival Results in First-Line PD-L1-Positive Non-Small Cell Lung Cancer

AI-generated NewsSnap summary based on source reporting.
Published: 2026-09-13
Category: health
Source: PR Newswire

Akeso, Inc. announced positive overall survival results from the Phase III HARMONi-2 study of ivonescimab versus pembrolizumab in patients with first-line PD-L1-positive non-small cell lung cancer (NSCLC). These findings were presented at the 2026 World Conference on Lung Cancer (WCLC).

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai